Diversified Trust Co Buys 25,304 Shares of IQVIA Holdings Inc. $IQV

Key Points

• Diversified Trust Co significantly increased its stake in IQVIA Holdings Inc. by 1,415.2%, acquiring an additional 25,304 shares, bringing its total ownership to 27,092 shares valued at approximately $4.27 million.
• Several hedge funds have also adjusted their positions in IQVIA, with 89.62% of the stock now held by institutional investors, indicating strong institutional interest in the company.
• Wall Street analysts are optimistic about IQVIA, with 18 analysts rating the stock as a "Buy," and a consensus target price raised to $229.64 following positive earnings results and performance guidance.

Diversified Trust Co increased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 1,415.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 27,092 shares of the medical research company's stock after acquiring an additional 25,304 shares during the quarter. Diversified Trust Co's holdings in IQVIA were worth $4,269,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. Brighton Jones LLC raised its position in shares of IQVIA by 244.4% during the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company's stock worth $703,000 after acquiring an additional 2,537 shares in the last quarter. State of Wyoming lifted its stake in shares of IQVIA by 52.5% during the fourth quarter. State of Wyoming now owns 851 shares of the medical research company's stock worth $167,000 after purchasing an additional 293 shares in the last quarter. Waverly Advisors LLC acquired a new stake in IQVIA in the fourth quarter valued at $626,000. Continuum Advisory LLC raised its holdings in shares of IQVIA by 3.7% during the fourth quarter. Continuum Advisory LLC now owns 1,803 shares of the medical research company's stock worth $354,000 after purchasing an additional 64 shares during the period. Finally, Vise Technologies Inc. acquired a new stake in shares of IQVIA in the 4th quarter worth about $254,000. Institutional investors and hedge funds own 89.62% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. Truist Financial lifted their target price on IQVIA from $209.00 to $235.00 and gave the stock a "buy" rating in a report on Wednesday, July 23rd. Evercore ISI upped their price target on shares of IQVIA from $170.00 to $180.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 9th. William Blair reiterated an "outperform" rating on shares of IQVIA in a research report on Wednesday, July 23rd. Mizuho lifted their target price on IQVIA from $190.00 to $225.00 and gave the company an "outperform" rating in a research report on Friday, July 25th. Finally, Barclays upped their price objective on shares of IQVIA from $165.00 to $185.00 and gave the company an "equal weight" rating in a report on Wednesday, July 23rd. Eighteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $229.64.

Insider Activity

In other news, insider Keriann Cherofsky sold 549 shares of IQVIA stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the transaction, the insider owned 2,910 shares in the company, valued at $557,352.30. This trade represents a 15.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Eric Sherbet sold 5,800 shares of IQVIA stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the completion of the transaction, the insider owned 27,178 shares of the company's stock, valued at $5,165,178.90. The trade was a 17.59% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is owned by company insiders.

IQVIA Stock Performance

Shares of IQV traded down $2.91 on Friday, reaching $187.29. 2,104,117 shares of the company's stock traded hands, compared to its average volume of 1,124,593. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $245.20. The stock's 50 day simple moving average is $184.79 and its two-hundred day simple moving average is $167.31. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.45. The stock has a market cap of $31.84 billion, a PE ratio of 27.10, a PEG ratio of 2.06 and a beta of 1.32.

IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The business had revenue of $4.02 billion during the quarter, compared to the consensus estimate of $3.96 billion. During the same period last year, the business posted $2.64 earnings per share. The business's revenue for the quarter was up 5.3% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.